BACE1 and Alzheimer disease: The lead candidate in the series is the APP selective small molecule FAH65 and its active enantiomer FAH65(-), which displays potent inhibition of BACE1 in vitro and in vivo, and elicits improvement in memory in an AD mouse model after oral treatment.